

14. A hybrid protein comprising one antigen-binding antibody fragment covalently linked to an albumin molecule or a fragment thereof, wherein the antibody fragment and albumin are indirectly linked by a bridging molecule between the thiol groups of a cysteine residue present in the antibody and another present in the albumin at position 34.
15. A hybrid protein according to Claim 14 wherein the bridging molecule is from around 10A to around 20A in length.
16. A hybrid protein according to Claim 15 wherein the bridging molecule is an optionally substituted hexylene chain.
17. A hybrid protein according to Claim 14 wherein the antibody fragment is a monovalent Fab fragment optionally containing one or more additional amino acids attached to the C-terminus of the CH1 domain.
18. A hybrid protein according to Claim 17 wherein the antibody fragment is a monovalent Fab or Fab' fragment.
19. A hybrid protein according to Claim 14 covalently linked to one or more effector or reporter groups.
20. A pharmaceutical composition comprising of a hybrid protein according to Claim 14 together with one or more pharmaceutically acceptable excipients, diluents or carriers.